Collateral Estoppel Provides Petitioner with Successful Shortcut in IPR Challenge

Jul 17, 2020

Reading Time : 2 min

Petitioner Alphatec Holding, Inc. filed an IPR petition alleging that five dependent claims of Patent Owner Nuvasive, Inc.’s patent (related to systems and methods of spinal fusion) would have been obvious. The board had previously considered the patentability of several claims of that patent in an IPR brought by another petitioner in 2013. In that IPR, the board held that independent claim 1 was obvious in light of a combination of two references. In 2016, the Federal Circuit affirmed the Board’s final written decision.

Here, Petitioner asserted a three-reference obviousness combination that included the two references previously held to render obvious independent claim 1. Petitioner argued that—as the board previously held—those references teach or suggest all limitations of claim 1. According to Petitioner, Patent Owner was estopped from arguing that claim 1 lent any support to the patentability of any dependent claim over those two references and that it was irrelevant that the exact three-reference ground was not previously considered. This was so, according to Petitioner, because there was already a final decision that two of those references taught or disclosed each limitation of claim 1. Patent Owner argued that Petitioner failed to meet each element of collateral estoppel. Here, according to Patent Owner, the issues are different from the previous IPR because Patent Owner could not have had a full and fair opportunity to litigate a three-reference ground that had never been raised. Patent Owner also argued, among other things, that in the prior IPR it did not have an adequate opportunity to respond to arguments made in that petitioner’s reply.

The board agreed with Petitioner. First, the board recognized that collateral estoppel prevents a patentee from asserting the validity of a claim that has been declared invalid in a prior proceeding if (1) the identical issue was litigated; (2) the issue was actually decided in a final decision on the merits; (3) the determination of the issues was necessary to the resulting judgment; and, (4) the party defending against preclusion had a full and fair opportunity to litigate the issues.

In its previous final written decision, the board determined the same issue presented here—that two references taught all limitations of claim 1. That issue was decided in a final decision and was necessary for the conclusion that claim 1 was unpatentable. As to the fourth element of collateral estoppel, Patent Owner failed to point to evidence that it did not have a full and fair opportunity to litigate the issue. The fact that Petitioner asserts an additional reference does not affect the previous final determination that the other two references teach and disclose all limitations of claim 1. And the board did not apply collateral estoppel to Petitioner’s asserted rationale for combining the references (which include the third, new, reference). Finally, the fact that Patent Owner did not make certain arguments in the prior IPR does not mean that estoppel does not apply. Accordingly, the board found that the prior determination precluded Patent Owner from relitigating whether the references teach all limitations of claim 1, as arranged in the claim, for purposes of determining patentability of dependent claims.

Practice Tip: When filing an IPR petition, a petitioner should consider whether a prior decision might collaterally estop the patent owner from contesting any issues on which petitioner carries the burden of proof. Specifically, if any related claims have already been held invalid or unpatentable in a prior decision, petitioners should consider whether that prior decision resolves the same issues with respect to the challenged claims. If so, those prior findings may be leveraged through collateral estoppel.

Alphatec Holdings, Inc. v. NuVasive, Inc., IPR2019-00361, Paper 59 (PTAB July 8, 2020)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.